SEATTLE — Apellis Pharmaceuticals reported there is no indication that drug product or manufacturing issues contributed to recent reports of retinal vasculitis linked with Syfovre.
“Following 68,000 commercial vials distributed and 23,000 clinical trial injections to date, these events continue to be very rare,” Cedric Francois, MD, PhD, co-founder and CEO of Apellis, said in a press release. “Additionally, as part of our ongoing review, we have seen no indication that drug product or manufacturing issues contributed to these events.”
Apellis has received seven